Introduction and Objective: This secondary analysis of the GO MOMs cohort evaluated associations of first trimester maternal BMI, CGM, OGTT, HbA1c and metabolic measures with newborn adiposity.Methods: At 9 US centers gravidas with singletons and no pre-existing diabetes underwent 75g OGTT, HbA1c, CGM and fasting lipid measures (free fatty acids-FFA; triglycerides-TG) at 10-14 weeks’ gestation. Insulin sensitivity (IS) and beta cell function (βCF) were calculated. Newborn measures at <72 hours of life yielded estimates of fat mass (FM), percent body fat (%BF), and waist/length ratio (WLR). Linear regression models, adjusted for multiple covariates, assessed associations between first trimester exposures and newborn adiposity. Results were stratified by newborn sex if interaction terms were significant.Results: 1555 (71%) participants had complete measures. In adjusted regression models (Table), for BMI higher by 1 SD, newborn FM was higher by 26g, %BF by 0.54%, and WLR by 0.61. Similarly, for fasting glucose higher by 1 SD, FM was higher by 18.5g, %BF by 0.37%, and WLR by 0.36. Nocturnal and 24hr mean CGM glucose were positively associated with FM and %BF. HbA1c was positively associated with WLR and, in females, FM. IS, βCF, FFA and TG were not associated with any adiposity measure.Conclusion: First-trimester maternal BMI, fasting glucose, CGM-measured glycemia, and HbA1c were positively associated with higher measures of newborn adiposity.
K. Vesco: None. F.L. Facco: None. M. Feghali: None. W. Grobman: None. A.A. Killeen: None. E. LeBlanc: None. W. Lowe: None. A. Merriam: None. M. Mourad: None. C. Oshiro: None. C. Powe: Research Support; Current; Dexcom, Inc. Other – Associate Editor of Diabetes Care, Honoraria for Educational Materials; Current; American Diabetes Association. Other – Royalties for Up To Date chapters; Current; Wolters Kluwer (Up To Date). Other – Speaker; Ended; Medscape. U. Reddy: None. D. Rouse: None. D. Scholtens: None. J. Sherr: Other – research support, consultant, advisory board member; Current; Abbott Diabetes. Other – advisory board member, consultant; Current; Vertex Pharmaceuticals Incorporated. Consultant; Current; Ypsomed AG. Research Support; Current; Dexcom, Inc., JDRF, Provention Bio, Inc., National Institutes of Health. Other – research support, consultant, advisory board member; Current; Insulet Corporation, Medtronic. Research Support; Current; Sanofi. Advisory Panel; Current; sequel med tech. A.C. Spadola: None. E. Werner: None. L.M. Yee: None. N. Zork: None. N. Lancki: None. P. Catalano: None.
The GO MOMs study is supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases. U01DK123795 to Massachusetts General Hospital; U01DK123791 to Kaiser Permanente; U01DK123759 and U01DK123745 to Northwestern University; U01DK123799 to Yale University; U01DK123783 to Women & Infants Hospital of Rhode Island. Dexcom provided the CGM systems used in the study free of charge.
Source link
Leave a Reply